Trial
NCT05582694
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
—
Condition
Multi-Drug Resistant Hiv-1 Infection
Intervention
UB-421
Why stopped
Difficulty with recruitment and drug production.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-11